La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Pliant Therapeutics Croissance future

Future contrôle des critères 2/6

Les bénéfices de Pliant Therapeutics devraient diminuer de 4.6% par an tandis que son chiffre d'affaires annuel devrait croître de 74.9% par an. Le BPA devrait croître de de 4.1% par an. Le rendement des capitaux propres devrait être -156.1% dans 3 ans.

Informations clés

-4.6%

Taux de croissance des bénéfices

4.1%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.6%
Taux de croissance des recettes	74.9%
Rendement futur des capitaux propres	-156.1%
Couverture par les analystes	Good
Dernière mise à jour	12 Aug 2024

Mises à jour récentes de la croissance future

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:PLRX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	4	-299	-253	-230	10
12/31/2025	6	-268	-216	-209	12
12/31/2024	2	-223	-172	-181	12
6/30/2024	N/A	-185	-140	-137	N/A
3/31/2024	0	-171	-119	-116	N/A
12/31/2023	2	-161	-117	-116	N/A
9/30/2023	4	-155	-124	-122	N/A
6/30/2023	5	-144	-106	-105	N/A
3/31/2023	10	-133	-106	-104	N/A
12/31/2022	10	-123	-96	-95	N/A
9/30/2022	10	-113	-85	-83	N/A
6/30/2022	10	-109	-89	-87	N/A
3/31/2022	7	-103	-85	-82	N/A
12/31/2021	8	-97	-77	-75	N/A
9/30/2021	10	-92	-74	-72	N/A
6/30/2021	13	-81	-67	-65	N/A
3/31/2021	15	-75	-40	-38	N/A
12/31/2020	42	-42	-39	-37	N/A
9/30/2020	94	18	15	16	N/A
6/30/2020	90	19	16	17	N/A
3/31/2020	86	20	-6	-5	N/A
12/31/2019	57	-7	-4	-3	N/A
3/31/2019	N/A	-43	-33	-32	N/A
12/31/2018	N/A	-35	-31	-28	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: PLRX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: PLRX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: PLRX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PLRX ( 74.9% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PLRX ( 74.9% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: PLRX devrait être non rentable dans 3 ans.

Pliant Therapeutics Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates decrease by 69%, EPS upgraded

Price target decreased by 7.1% to US$42.67

Price target decreased by 9.4% to US$44.08

Consensus revenue estimates decrease by 20%, EPS upgraded

Consensus revenue estimates fall by 32%

Consensus revenue estimates increase by 11%

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

Pliant Therapeutics, Inc. Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2500 Growth Index

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 69%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.1% to US$42.67

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$44.08

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Consensus revenue estimates fall by 32%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Business Officer notifies of intention to sell stock

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 123%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel & Corporate Secretary notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

President notifies of intention to sell stock

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Price target increased by 17% to US$49.09

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

President notifies of intention to sell stock

Insufficient new directors

General Counsel & Corporate Secretary notifies of intention to sell stock

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$256k worth of stock

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics: Wait For A Better Price To Get In

Consensus revenue estimates increase by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant's PLN-74809 gets FDA fast track status for liver disease

Price target increased to US$43.71

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant: Major Catalyst Expected Beginning Of 2023

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

Price target decreased to US$39.67

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate